Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
6(75.0%)
Phase 1
2(25.0%)
8Total
Phase 2(6)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04919239Phase 2Completed

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)

Role: lead

NCT05455112Phase 2Completed

Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis

Role: lead

NCT03191578Phase 1Completed

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Role: lead

NCT05115019Phase 2Withdrawn

A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)

Role: collaborator

NCT05136833Phase 2Withdrawn

Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients

Role: lead

NCT02711735Phase 2Terminated

Safety of RUTI® Vaccination in MDR-TB Patients

Role: lead

NCT01136161Phase 2Completed

Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

Role: lead

NCT00546273Phase 1Completed

Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers

Role: collaborator

All 8 trials loaded